{Reference Type}: Journal Article
{Title}: Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy.
{Author}: Chu P;Batson S;Hodgson M;Mitchell CR;Steenrod A;
{Journal}: Future Oncol
{Volume}: 16
{Issue}: 4
{Year}: Feb 2020
{Factor}: 3.674
{DOI}: 10.2217/fon-2019-0534
{Abstract}: Aim: To conduct a systematic review and meta-analysis feasibility of clinical, quality of life and economic evidence for neurotrophic tropomyosin-related receptor tyrosine kinases (NTRK) inhibitors in patients with NTRK gene fusion-positive tumors. Materials & methods: Databases were searched for studies on NTRK inhibitors in adult and pediatric patients. Results: 27 publications reported clinical data for seven interventions. Efficacy/safety data were available for two interventions only. Four trials each reported data for larotrectinib and entrectinib with pooled analyses reporting objective response rates of 75% (95% CI: 61-85) and 57.4% (43.2-70.8), respectively. No publications reported economic or quality of life evidence. Conclusion: Preliminary data demonstrate that NTRK inhibitors are well tolerated and show impressive clinical benefit; corroboration of existing studies and real-world data are required.